The Hippo Kinase Pathway: a master regulator of proliferation, development and differentiation by Lo, Sardo F et al.
  
 
 
   
Deep Insight Section 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 19(1) 65 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS 
 
OPEN ACCESS JOURNAL 
The Hippo Kinase Pathway: a master regulator 
of proliferation, development and 
differentiation 
Federica Lo Sardo, Sabrina Strano, Giovanni Blandino 
Translational Oncogenomic Unit, Regina Elena Cancer Institute, via Elio Chianesi 53, 00144 Rome, 
Italy (FLS, GB), Molecular Chemoprevention Unit, Italian National Cancer Institute "Regina Elena", 
00144 Rome, Italy (SS) 
 
Published in Atlas Database: May 2014 
Online updated version : http://AtlasGeneticsOncology.org/Deep/HippoKinaseID20125.html 
DOI: 10.4267/2042/55383 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2015 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Abstract 
Hippo signaling transduction pathway is widely conserved through evolution and controls cell growth, 
homeostasis, apoptosis, commitment, differentiation and senescence. It consists of a conserved kinase cascade 
whose final targets are the transcriptional coactivator Yorkie (Yki) in Drosophila and the homologues YAP and 
TAZ in mammals. These transcriptional coactivators are unable to bind DNA per se, and can regulate the 
activity of their target genes only in association with transcription factors. In Drosophila, Yki associates with the 
transcription factors Sd and Hth regulating pro-proliferative and anti-apoptotic genes. In mammals instead, 
YAP/TAZ can associate with several distinct transcription factors. This depends from the type of signals to 
which cells are subjected, the cell type and the developmental stage. The transcriptional outcome resulting from 
this association can be either pro-apoptotic or pro-proliferative. Hippo pathway dysregulation has been 
associated with several pathologic conditions (tissue overgrowth, developmental defects and cancer). In 
particular, solid tumors show an upregulation or hyperactivation of YAP/TAZ, while several hematologic tumors 
are associated with YAP downregulation. This might suggest that the Hippo pathway holds the potential to be an 
attractive target for novel therapeutic approaches for cancer. 
 
Introduction 
Hippo signal transduction pathway is an 
evolutionary conserved pathway, from flies to 
humans, that controls organ size, development, 
tissue regeneration-homeostasis and stem cell self-
renewal through the regulation of cell proliferation, 
cell commitment and apoptosis. Components of the 
pathway include membrane associated proteins that 
sense cell polarity, cell density and mechanical 
cues, that in turn activate a cascade of kinases 
whose final target is the transcriptional coactivator 
Yorkie (Yki) in Drosophila, or its mammalian 
counterparts Yes Associated Protein (YAP) and 
Transcriptional coactivator with PDZ-binding motif 
(TAZ, also called WWTR1). These factors are 
unable to bind DNA per se, but can regulate 
transcription in association with other transcription 
factors. 
Aberrant regulation of the Hippo pathway is 
associated with tissue overgrowth and various types 
of cancers in mammals (see below). Thus, a major 
comprehension of the mechanisms at the basis of 
YAP/TAZ upstream regulation and downstream 
transcriptional response could also be relevant for 
the characterization of prognostic factors in cancer 
and for the development of novel anti-cancer 
therapies. 
Hippo pathway core components 
The core components of the Hippo pathway were 
firstly discovered in Drosophila melanogaster by 
mosaic genetic screens which showed a strong 
overgrowth phenotype shared by loss-of-function 
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mutants. Based on these findings, the Hippo 
pathway had been defined as an oncosuppressor 
pathway. In parallel, homologous components of 
the pathway were discovered in other organisms, 
including mammals (reviewed in Varelas and 
Wrana, 2012). Some of them are able to rescue 
mutant phenotypes in flies (Lai et al., 2005; Tao et 
al., 1999; Wu et al., 2003). The Hippo pathway core 
components are listed in table 1 and schematically 
represented in Figure 1. 
They include two serine/threonine kinases 
associated with adaptor proteins: the first is the 
STE20 kinase Hippo (Hpo) with the adaptor protein 
Salvador (Sav) (MST1/2 and Sav1 in mammals) 
(Callus et al., 2006; Harvey et al., 2003; Jia et al., 
2003; Kango-Singh et al., 2002; Pantalacci et al., 
2003; Tapon et al., 2002; Udan et al., 2003; Wu et 
al., 2003), and the second is the NDR kinase Warts 
(Wts) associated with the scaffold protein Mats, 
(Lats1/2 associated with Mob1 in mammals) 
(Callus et al., 2006; Chan et al., 2005; Praskova et 
al., 2008; Wu et al., 2003). Drosophila Hpo and 
mammalian MST1/2 directly bind Sav protein and 
are able to phosphorylate and activate Sav itself and 
Mats (Sav1 and Mob1 mammalian counterparts). 
Drosophila Mats and mammalian Mob1 interact 
with and phosphorylate Wts and Lats1/2, 
respectively. Wts-Mats and Lats1/2-Mob 
phosphorylate in turn specific residues of the 
transcriptional coactivator Yki and its mammalian 
counterparts YAP and TAZ. Yki and YAP/TAZ 
phosphorylation result in their cytoplasmic 
sequestration via 14-3-3 binding (Dong et al., 2007; 
Haoet al., 2008; Kanai et al., 2000; Lei et al., 2008; 
Vassilev et al., 2001; Zhao et al., 2007), which 
inhibits TAZ/YAP nuclear functions as 
transcriptional coactivators, while promoting their 
cytoplasmic role (Varelas et al., 2010) or their 
proteasomal degradation (Liu et al., 2010; Zhao et 
al., 2010).  
It is becoming clear that not only Hippo pathway 
core kinases are able to regulate YAP and TAZ 
nuclear activity. For example, recently it has been 
shown that SIRT1 protein is able to activate YAP2  
isoform by deacetylation in hepatocellular 
carcinoma cells (HCC) (Mao et al., 2014). 
Moreover, YAP and TAZ are at the crossroad 
between several other signalling pathways as Wnt, 
Tgfβ and Notch (reviewed in Barry and Camargo, 
2013). Conversely, Hippo pathway core 
components may be involved in cell cycle control 
independently of YAP/TAZ regulation. For 
example, Mst1 has been shown to promote 
apoptosis in injuried cardiomiocytes independently 
of YAP phosphorylation (Maejima et al., 2013). In 
this case, Mst1 has been shown to phosphorylate 
beclin1, a protein that alternatively binds Atg14L-
Vps34 or Bcl-2 protein. In normal conditions, 
beclin1 complexes with Atg14L-Vps34 to promote 
autophagy, a process required for the recycling of 
macromolecular proteins and damaged organelles. 
Meanwhile, Bcl-2 sequesters Bax and inhibits 
apoptosis. Mst1 phosphorylates Beclin1 at Thr108 
during cellular stress. This causes Beclin1 
dissociation from Atg14L-Vps34 and its association 
with Bcl-2 that is no more able to sequester Bax. 
This in turn leads to apoptosis. 
Upstream regulators of Hippo 
pathway core components 
Proteins involved in cell junction, cell polarity and 
G-protein-coupled receptor (GPCR) signalling are 
upstream regulators of the core Hippo pathway. 
These proteins regulate YAP/TAZ nuclear activity 
in response to both mechanical and biochemical 
stimuli originated from the extracellular matrix 
(ECM). 
Cell junction/cell polarity: in vivo, epithelial cells 
are in contact each another through specialized 
cellular junctions, forming sheets that line the 
surface of the animal body and internal cavities (for 
example digestive and circulatory cavities). These 
cells are oriented in the space with an apical-basal 
polarity: the apical membrane is oriented to the 
outside surface of the body, or the lumen of internal 
cavities, and the basolateral membrane is oriented 
away from the lumen. Polarity proteins associate 
with junction proteins in order to contribute to their 
proper localization and assembly and thereby to the 
functional organization of the tissues.  
 
Table 1: Hippo pathway core components 
 
The Hippo Kinase Pathway: a master regulator of proliferation,  Lo Sardo F, et al. 
development and differentiation 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 19(1) 67 
 
Figure 1. Schematic representation of Hippo pathway core components, their upstream regulators and transcriptional 
outcome in Drosophila (left) and mammals (right). In figure1, the Extracellular Matrix (ECM), the cytoplasm and the nucleus 
of cells are represented. Proteins are represented in various colours, with homologous components between Drosophila and 
mammals represented with the same colour. Black arrows indicate activation, while blunt lines indicate inhibition. Light blue 
arrows indicate phosphorylation of proteins by kinases. Orange balls indicate phosphorylation sites of target proteins. The Hippo 
pathway core kinase cassette is represented inside a black rectangle. For simplicity, junction proteins and polarity proteins are 
not represented by the specific Drosophila or mammalian subunits. In general, even if they are represented by different 
complexes in Drosophila or mammals, either homologous or not, they inhibit Yki and YAP/TAZ nuclear activity by sequestering 
them at the apical membrane or by interacting with and activating the Hippo pathway core kinases (represented in the black 
rectangle) that in turn inhibit Yki and YAP/TAZ nuclear activity. In mammals, GPCR signalling and mechanical stress coming 
from the ECM activate Rho GTPase that in turn stabilizes the actin cytoskeleton thus inhibiting Hippo pathway core kinases (and 
activating YAP/TAZ nuclear activity). In the nucleus, Drosophila Yki interacts with Sd or Hth transcription factors and activates 
pro-proliferative and anti-apoptotic genes. Mammalian YAP and TAZ instead interact with several different transcription factors 
(see also table 3) and the resulting transcriptional outcome may be either pro-proliferative or pro-apoptotic. This might depend 
from the incoming signals to which cells are exposed and from the specificity of the associated transcription factor. 
 
The Kibra complex, conserved in Drosophila and in 
mammals, represents an example of apical proteins 
involved in Hippo pathway regulation. It recruits 
Hippo pathway core components like Hpo and Sav 
to the apical plasma membrane for activation, thus 
inhibiting YAP/TAZ nuclear activity and tissue 
growth (Genevet et al., 2010; Yu et al., 2010). Also 
the Crumbs polarity complex, the Scribble complex 
and Par3 polarity complex have been shown to be 
negative regulators of YAP and TAZ nuclear 
function (Chen et al., 2010; Gurvich et al., 2010; 
Ling et al., 2010; Robinson et al., 2010; Varelas et 
al., 2010). Other polarity proteins as Ajuba and 
LKB1 have been shown to negatively regulate YAP 
and TAZ nuclear function (Das Thakur et al., 2010; 
Nguyen et al., 2013). Moreover, many cell junction 
associated proteins, such as angiomotin (AMOT), 
MPDZ, PATJ, PALS1, LIN7C, PTPN14, ZO-1, a-
β-catenin and E-cadherin have been identified as 
interacting partners or regulators of Hippo pathway 
core components (Kim et al., 2011; Liu X et al., 
2013; Oka et al., 2010; Remue et al., 2010; 
Schlegelmilch et al., 2011; Zhao et al., 2011). 
In general, these proteins negatively regulate 
YAP/TAZ nuclear function by sequestering 
YAP/TAZ to the apical plasma membrane, thus 
excluding them from the nucleus, and by interacting 
with and activating hippo pathway core kinases. 
This in turn inhibits YAP and TAZ nuclear function 
by phosphorylation (Genevet et al., 2010; Varelas 
et al., 2010; Yu et al., 2010; Zhao et al., 2011). 
Indeed, disruption of cellular junctions or 
downregulation of cell polarity/cell junction 
proteins leads to YAP/TAZ activation (Chen et al., 
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2010; Cordenonsi et al., 2011; Dupont et al., 2011; 
Varelas et al., 2010). Thus, YAP and TAZ nuclear 
function is inhibited by cell contact to finely tune 
the proliferation of cells within a tissue and an 
organ during physiological tissue-organ growth and 
regeneration. However, there are few exception to 
this rule: NPHP4 (nephronophthisis 4) can interact 
with and inhibit Lats1 (Habbig et al., 2011) and 
ZO-2 (zona occludens-2) can induce YAP nuclear 
localization (Oka et al., 2010). The regulation of 
Hippo pathway by apical-basal polarity and cell 
junction is largely conserved in Drosophila and 
mammals, even if not all the proteins are conserved 
between flies and vertebrates (Bossuyt et al., 2014). 
Biochemical signals: very recently, several groups 
have shown that diffusible signals and metabolites 
like LPA, S1P, thrombin and statins regulate 
YAP/TAZ function (Miller et al., 2012; Mo et al., 
2012; Sorrentino et al., 2014; Yu et al., 2012). LPA, 
S1P and thrombin activate G-protein coupled 
receptor (GPCR) which usually activate 
downstream signalling through heterotrimeric G 
proteins that in turn activate the mediator Rho 
GTPase. Depending on which Gα protein is 
activated, YAP and TAZ may be either activated or 
repressed. In fact, Gα12/13-, Gαq/11-, or Gαi/o-coupled 
signals induce YAP/TAZ activity, whereas Gαs-
coupled signals repress YAP/TAZ activity (Mo et 
al., 2012; Yu et al., 2012). Rho GTPase are also 
regulated by mevalonate pathway. Recently in 
Sorrentino lab it has been shown that statins, by 
inhibiting the mevalonate biosynthesis, prevent Rho 
GTPase activation and thus Yki and YAP/TAZ 
nuclear function (Sorrentino et al., 2014). 
Mechanical cues: in vivo, cells are subjected to 
mechanical stimulation coming from neighbouring 
cells, the ECM and surrounding biological fluids. 
These signals influence cell proliferation and 
migration, and cytoskeletal changes are at the basis 
of cellular responses to these mechanical stimuli. It 
has been recently shown that YAP and TAZ are 
regulated by changes in the actin cytoskeleton in 
response to mechanical cues experienced by the 
cell. In particular, cell adhesion, cell geometry, cell 
shape, cell suspension and extracellular matrix 
stiffness have been shown to regulate YAP/TAZ 
nuclear activity in different experimental reports. 
When cells are grown at low cell density, or on a 
stiff extracellular substrate, or also on a large 
adhesive island, conditions where the cell-ECM 
contact area is broad and the cytoskeleton is 
subjected to a stronger mechanical stimulation YAP 
and TAZ are predominantly localized in the 
nucleus. Conversely, YAP/TAZ effectors 
translocate to the cytplasm in response to high 
cellular density/cell contact, on a soft extracellular 
substrate or on micropatterned small islands, 
conditions in which the cell experience a small cell- 
ECM contact area and a low mechanical stress. 
(Dupont et al., 2011; Wada et al., 2011; Zhao et al., 
2012; Zhao et al., 2007) . YAP and TAZ are not 
only mechanosensors, but also mechanoeffectors 
because, once activated, they are able to regulate in 
turn genes involved in extracellular matrix 
remodelling (Calvo et al., 2013). 
It is still not completely clear how mechanical and 
biochemical cues experienced by the cell are linked 
with YAP and TAZ activity. It has been shown that 
both RHO GTPases and the actin cytoskeleton are 
able to transduce these upstream signals to YAP 
and TAZ. In particular, F-actin stabilization and 
RHO-GTPase activation (depending on the 
activated Gα protein) are able to activate 
YAP/TAZ, while F-actin destabilization determines 
YAP/TAZ inhibition. However, the gap between 
YAP and TAZ and these upstream transducers 
remains to be fulfilled. 
YAP-TAZ effectors and their 
transcriptional targets 
YAP mRNA is ubiquitously expressed in a wide 
range of mammalian tissues, with the exception of 
peripheral blood leukocytes (Komuro et al., 2003), 
it is expressed in all developmental stages from 
blastocyst to perinatal and it is necessary for a 
correct and vital embryonic development. TAZ 
instead shows a later onset, it is present in all the 
embryonic stages with the exception of blastocyst 
stage (Morin-Kensicki et al., 2006). YAP and TAZ 
per se are not able to bind DNA, but they regulate 
gene targets expression (either by activation or 
repression) through interaction with transcription 
factors in a tissue and development specific 
manner.  
By now, several YAP and TAZ interacting proteins 
have been characterized among which some are 
able to sequester or post-transcritpionally modify 
YAP and TAZ (table2) (Chan et al., 2011; Chen 
and Sudol, 1995; Espanel and Sudol, 2001; Howell 
et al., 2004; Hsu and Lawlor, 2011; Koontz et al., 
2013; Mohler et al., 1999; Rosenbluh et al., 2012; 
Sudol, 1994; Tsutsumi et al., 2013), others are 
transcriptional regulators (table3) (Cui et al., 2003; 
Di Palma et al., 2009; Ferrigno et al., 2002; Hong et 
al., 2005; Hsu and Lawlor, 2011; Jeong et al., 2010; 
Kang et al., 2009; Murakami et al., 2005; Wang J et 
al., 2013; Xiao et al., 2013; Yagi et al., 1999). All 
the components of the Hippo pathway, from the 
membrane associated proteins to the cytoplasmic 
kinase cascade to the final effectors YAP and TAZ, 
are characterized by specific protein-protein 
interaction domains, among which the most 
common are WW domain and the similar SH3 
domain, able to bind short peptides that are prolin-
rich and often terminate with Tyrosine (Y), named 
PpxY motifs (Sudol and Hunter, 2000). 
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Table 2: YAP/TAZ interactors in mammals (regulative proteins) 
 
 
There are two major YAP splicing variants with 
one (YAP1) or two (YAP2) WW domains, but 
recently, eight different spliced mRNA isoforms of 
YAP1 gene have been characterized and identified 
in a panel of human tissues (Gaffney et al., 2012). 
The different splicing variants of YAP, the different 
post-transcriptional modifications of YAP and 
TAZ, and the different chromatin state of target 
genes may select different repertoires of proteins in 
transcriptional complexes and affect the gene 
expression program in a developmental and tissue-
specific manner (Beyer et al., 2013; Reginensi et 
al., 2013; Slattery et al., 2013).  
The transcription factors with which YAP and TAZ 
cooperate are directly involved in control of cell 
proliferation/survival or apoptosis, like TEAD 
(Chan et al., 2009; Mahoney et al., 2005; Ota and 
Sasaki, 2008; Vassilev et al., 2001; Zhang et al., 
2009; Zhao et al., 2008) and p73 transcription 
factors, (Strano et al., 2001) or are components of 
other signalling pathways as Wnt, EGFR, JAK/Stat, 
BMP-TGFbeta involved in embryonic development 
and adult tissue homeostasis. For example, it has 
been shown that YAP/TAZ interact with Smad 
proteins (Smad1, Smad2, Smad3) to enhance the 
transcription of genes responsive to BMP-TGFbeta 
signalling (Alarcon et al., 2009; Schlegelmilch et 
al., 2011; Varelas et al., 2010). Other transcriptional 
targets are represented by components of the Hippo 
pathway. 
 
Table 3: YAP/TAZ interactors in mammals (transcription factors). 
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Table 4: Tumor tissues or tumor cell lines where YAP/TAZ are overexpressed or hyperactivated. 
 
 
The dual role of YAP as an 
oncoprotein or an 
oncosuppressor 
A lot of studies supported the functional 
conservation of the core Hippo pathway 
components between Drosophila and mammals in 
the control of cell proliferation.  
When Hippo kinase pathway is inactive, YAP and 
TAZ enter the nucleus and affect transcription of 
different sets of target genes in a tissue and 
developmental specific manner (Beyer et al., 2013; 
Slattery et al., 2013).  
Increasing evidences showed that the transcriptional 
outcome in response to YAP/TAZ activation can be 
opposite.  
In mammals, it has been shown that YAP 
transcriptional coactivator can function either as an 
oncogene, or as a tumor suppressor, depending on 
the signals to which cells are subjected and on the 
transcription factors with which YAP is associated. 
The emerging and intriguing dual role of YAP and 
the mechanisms determining the two exclusive 
cellular responses (pro-proliferative or pro-
apoptotic) are still not entirely understood as they 
were built on classic studies performed in different 
cell types and tissues.  
Here, we will discuss experimental evidences 
showing YAP as an oncogene or as an 
oncosuppressor. 
YAP as an oncogene 
There are several evidences supporting a pro-
proliferative and pro-oncogenic role of YAP (and 
TAZ) in mammalian systems. In humans, YAP is 
present in the 11q22 amplicon that is amplified in a 
lot of solid tumors (Baldwin et al., 2005; Bashyam 
et al., 2005; Dai et al., 2003; Hermsen et al., 2005; 
Imoto et al., 2002; Imoto et al., 2001; Lambros et 
al., 2005; Overholtzer et al., 2006; Snijders et al., 
2005; Weber et al., 1996) (Table 4).  
The syntenic chromosomal region in mouse 
contains YAP gene that is amplified in mammary 
and liver tumors (Overholtzer et al., 2006; Zender 
et al., 2006).  
Ectopic expression or hyperactivation of YAP 
promotes cell growth and induces oncogenic 
transformation and epithelial-mesenchimal 
transition (EMT) that is often associated with 
metastasis (Lamar et al., 2012; Lau et al., 2014; 
Nallet-Staub et al., 2013; Overholtzer et al., 2006; 
Zhao et al., 2009; Zhao et al., 2008).  
In mouse, transgenic YAP overexpression or liver-
specific knockout of Mst1/2 and Sav1 increases the 
number of stem/progenitor cells and determines 
liver overgrowth in a reversible manner, ultimately 
leading to hepatocellular carcinoma (HCC) 
(Camargo et al., 2007; Dong et al., 2007; Lee et al., 
2010; Lu et al., 2010; Song et al., 2010; Zhou et al., 
2009).  
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Consistently, a lot of human cancers show 
overexpression or hyperactivation of nuclear YAP 
or TAZ or downregulation of Lasts1/2, Mst1/2 or 
Sav1 function (Dong et al., 2007; Hall et al., 2010; 
Jiang et al., 2006; Matsuura et al., 2011; Muramatsu 
et al., 2011; Nallet-Staub et al., 2013; Quan et al., 
2014; Seidel et al., 2007; Steinhardt et al., 2008; Su 
et al., 2012; Takahashi et al., 2005; Wang L et al., 
2013; Wang et al., 2012; Wang et al., 2010; 
Wierzbicki et al., 2013; Xu et al., 2011; Xu et al., 
2009; Yuen et al., 2013; Zender et al., 2006; Zhao 
et al., 2007; Zhou Z et al., 2011) see also table 4. 
Moreover, overexpression or hyperactivation of 
YAP and TAZ have been associated with poor 
prognosis and shorter survival times for patients in 
several human cancers (Hall et al., 2010; Liu JH et 
al., 2013; Muramatsu et al., 2011; Wang et al., 
2010; Xu et al., 2009; Zhang et al., 2011). It has 
been also shown that Mst1/2 and Sav1 knockout, or 
YAP activation expanded the stem and the 
progenitor cell population in the intestine and in the 
skin in mouse (Lee et al., 2008; Schlegelmilch et 
al., 2011; Zhou D et al., 2011). YAP has been 
shown to contribute also to the expansion of 
neuroprogenitor cells (Cao et al., 2008). In addition, 
YAP has been found to be upregulated in mouse 
Embryonic Stem cells (mES) and in induced 
pluripotent stem cells (iPS) and to contribute to 
their stemness by binding and activating a large 
number of genes known to be important for stem 
cell maintenance (Lian et al., 2010). 
TAZ is overexpressed in breast cancer stem cells 
and is required to maintain their self-renewal 
capacity, tumorigenicity and ability to promote the 
formation of metastasis (Bartucci et al., 2014; Chan 
et al., 2008; Cordenonsi et al., 2011). Moreover, 
YAP and TAZ have been recently found to be 
upregulated in mouse wounds and to be required for 
wound closure (Lee et al., 2014). Based on these 
results, YAP and TAZ are defined as oncogenes 
and as "stemness genes" (Ramalho-Santos et al., 
2002).  
TEAD transcription factors guides YAP and TAZ 
onto pro-proliferative genes (Chan et al., 2009; 
Lamar et al., 2012; Mahoney et al., 2005; Zhang et 
al., 2009; Zhao et al., 2008). 
YAP as a tumor suppressor 
We originally showed that the tumor suppressor 
p73 protein, which belongs to the p53 family, has 
been shown to guide YAP onto pro-apoptotic 
targets. These findings together with other 
evidences from diverse labs indicated that YAP 
might behave as a tumor suppressor, in particular 
upon DNA damage signalling and serum 
deprivation (Lapi et al., 2008; Oka et al., 2008; 
Strano et al., 2005; Strano et al., 2001; Yuan et al., 
2008). p73-YAP interaction is increased upon DNA 
damage (Strano et al., 2005), where it has been  
shown to be phosphorylated by c-Abl that stabilizes 
both YAP and p73 and increases YAP/p73 
interaction (Levy et al., 2008). On the other hand, 
p73-YAP interaction is inhibited upon Akt-
mediated YAP phosphorylation (Basu et al., 2003). 
p73 is post-transcriptionally stabilized by YAP 
binding that competes with the E3 ubiquitin ligase 
ITCH, thereby preventing proteasomal degradation 
of p73 (Levy et al., 2007). YAP binding also 
induces p73 acetylation and transcriptional activity 
by recuiting the p300 acetyltranferase to target 
genes (Strano et al., 2005). Another 
oncosuppressor, PML (Promyelocytic leukemia 
protein) has been shown to act together with YAP 
and p73 as a mediator onto several proapoptotic 
target genes following DNA damage by physically 
interacting with both p73 and YAP (Bernassola et 
al., 2004; Lapi et al., 2008). PML is a key 
component and organizer of nuclear compartments 
termed nuclear bodies (NBs) implicated in 
processes such as transcriptional regulation, 
genome stability, response to viral infection, 
metabolism, apoptosis, and cell cycle control 
(reviewed in Gamell et al., 2014). It has also been 
proposed that PML partially collaborates with YAP 
and p73 in the proapoptotic response induced by 
DNA damage by several self-reinforcing 
mechanisms. First, YAP requires PML and NBs 
localization to coactivate p73 and, conversely, YAP 
and p73 are required for PML accumulation and 
PML-NB formation in response to DNA damage. 
Second, PML stabilizes YAP from proteasomal 
degradation by inducing its sumoylation and its 
recruitment into PML-nuclear bodies, where it 
collaborates with YAP and p73 onto target genes. 
Third, PML itself is a transcriptional target of YAP-
p73-PML complex (Lapi et al., 2008; Strano et al., 
2005). 
Interestingly, it has been shown an important role 
for YAP in the regulation of cellular senescence in 
a functional cooperation with PML and p53 (Fausti 
et al., 2013; Xie et al., 2013). 
Finally, while in many solid cancers YAP behaves 
as an oncogene and is upregulated or hyperactivated 
(see above), in hematologic malignancies, including 
lymphomas, leukemias and multiple myelomas 
YAP is deleted or downregulated. Lower YAP 
expression level correlates with poorer prognosis 
and shorter survival of patients (Cottini et al., 
2014). In the context of hematologic malignancies, 
YAP downregulation is a mechanism by which 
cells escape apoptosis in the presence of DNA 
damage. In fact, in normal hematologic cells YAP 
is phosphorylated by c-abl that stabilizes YAP/p73 
interaction and increases their transcriptional 
activity onto pro-apoptotic genes in the presence of 
DNA damage (Levy et al., 2007; Levy et al., 2008), 
while in malignant cells, where YAP is 
downregulated or absent, the c-Abl/p73/YAP axis  
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is disrupted (Cottini et al., 2014). Collectively, 
these observations do not classify YAP as a real 
tumor suppressor, but as a transcriptional co-
activator that can directly or indirectly regulate 
different tumor suppressor pathways (as p53 family 
or PML). 
A better understanding of the role of the Hippo 
pathway in tumorigenesis assessed in different 
experimental and physiological/pathological 
conditions would be important for a more specific 
characterization of prognostic factors in cancer and 
for the development of anti-cancer therapies that 
often need to be adapted to the type of disease and 
to the individual patient. 
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